Lenalidomid Grindeks

Lenalidomide, the active ingredient in Lenalidomid Grindeks, is an immunomodulatory drug (IMiD) presented as an oral formulation for systemic use. It is employed in the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements. Our distribution network ensures reliable delivery and supports clinical needs across diverse markets.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone marrow. - Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle cell lymphoma: provides therapeutic benefit as part of combination regimens in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools. - Rash: skin irritation or redness. - Constipation: difficulty passing stool. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Anemia: significant drop in red blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers. - Embryo‑fetal toxicity: high risk of birth defects and pregnancy loss.

Before initiating lenalidomide therapy, several precautions and monitoring measures should be observed. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolic prophylaxis: assess need for anticoagulation in high‑risk patients. - Hematologic monitoring: regular CBC to detect neutropenia, anemia, thrombocytopenia. - Renal function: evaluate and adjust in patients with impaired kidney function. - Hepatic function: monitor liver enzymes in patients with liver disease. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increased risk of bleeding. - Immunosuppressants: may diminish immunomodulatory effects.

Moderate Interactions (Monitor Closely): - P-glycoprotein substrates: potential alteration of drug levels. - CYP450 inhibitors: possible increased lenalidomide concentrations. - Vaccines: live vaccines may pose infection risk.